Excessive Daytime Sleepiness - Pipeline Insight, 2025
Description
DelveInsight’s, “Excessive Daytime Sleepiness - Pipeline Insight, 2025” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Excessive Daytime Sleepiness pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Excessive Daytime Sleepiness: Overview
Excessive daytime sleepiness can be symptomatic of several underlying conditions rather than being a standalone ailment. Any disruption in an individual's ability to obtain restorative sleep at night can manifest as excessive daytime sleepiness. Common culprits contributing to this condition include sleep apnea, restless leg syndrome (RLS), depression, hypersomnia, and narcolepsy. Sleep apnea poses a potentially serious threat, marked by abnormal breathing patterns during sleep.
These irregularities can prompt frequent awakenings and diminish sleep quality, culminating in daytime drowsiness. Conversely, RLS prompts an irresistible urge to move one's legs, often accompanied by discomfort or pain, which disrupts sleep patterns and fosters daytime sleepiness. Depression is also a prevalent trigger for excessive daytime sleepiness, altering sleep architecture with difficulties in both onset and maintenance of sleep. Consequently, individuals may grapple with daytime lethargy. Hypersomnia, characterized by persistent daytime sleepiness and struggles to remain awake, differs from narcolepsy in the absence of sudden and involuntary sleep episodes.
Narcolepsy, a rarer and more severe condition, epitomizes excessive daytime sleepiness, often compounded by unpredictable bouts of slumber at inconvenient times. Individuals afflicted with narcolepsy may succumb to sleep without warning and find it challenging to stay alert during the day. Unlike hypersomnia, narcolepsy is typified by disrupted nighttime sleep, further compromising overall sleep quality. Given its chronic nature, managing narcolepsy necessitates ongoing treatment and care. To effectively address excessive daytime sleepiness, understanding its multifaceted causes is imperative. By identifying and treating the underlying conditions such as sleep apnea, RLS, depression, hypersomnia, or narcolepsy, tailored interventions can be devised to enhance sleep quality and mitigate daytime drowsiness.
""Excessive Daytime Sleepiness- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Excessive Daytime Sleepiness pipeline landscape is provided which includes the disease overview and Excessive Daytime Sleepiness treatment guidelines. The assessment part of the report embraces, in depth Excessive Daytime Sleepiness commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Excessive Daytime Sleepiness collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Excessive Daytime Sleepiness report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Excessive Daytime Sleepiness Emerging Drugs
AXS-12: Axsome Therapeutics
AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the treatment of narcolepsy. It is thought to modulate noradrenergic activity to promote wakefulness, maintain muscle tone and enhance cognition. Reboxetine has an extensive safety record in Europe and in over 40 countries where it’s approved for the treatment of depression. In narcolepsy, AXS-12 is supported by positive pre-clinical and Phase II clinical results. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Excessive Daytime Sleepiness.
ALKS 2680: Alkermes
ALKS 2680 is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. Orexin neuropeptides are important regulators of the sleep/wake cycle through OX2R activation, and loss of orexinergic neurons in the brain is associated with excessive daytime sleepiness and cataplexy in narcolepsy.1 ALKS 2680 was designed to address the underlying pathology of narcolepsy with the goal of improving duration of wakefulness and providing cataplexy control. Once-daily oral administration of ALKS 2680 is currently being evaluated in a phase II study for the treatment of idiopathic hypersomnia.
Further product details are provided in the report……..
Excessive Daytime Sleepiness: Therapeutic Assessment
This segment of the report provides insights about the different Excessive Daytime Sleepiness drugs segregated based on following parameters that define the scope of the report, such as:
Excessive Daytime Sleepiness: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Excessive Daytime Sleepiness therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Excessive Daytime Sleepiness drugs.
Excessive Daytime Sleepiness Report Insights
Current Treatment Scenario and Emerging Therapies:
Geography Covered
- Global coverage
Excessive Daytime Sleepiness: Overview
Excessive daytime sleepiness can be symptomatic of several underlying conditions rather than being a standalone ailment. Any disruption in an individual's ability to obtain restorative sleep at night can manifest as excessive daytime sleepiness. Common culprits contributing to this condition include sleep apnea, restless leg syndrome (RLS), depression, hypersomnia, and narcolepsy. Sleep apnea poses a potentially serious threat, marked by abnormal breathing patterns during sleep.
These irregularities can prompt frequent awakenings and diminish sleep quality, culminating in daytime drowsiness. Conversely, RLS prompts an irresistible urge to move one's legs, often accompanied by discomfort or pain, which disrupts sleep patterns and fosters daytime sleepiness. Depression is also a prevalent trigger for excessive daytime sleepiness, altering sleep architecture with difficulties in both onset and maintenance of sleep. Consequently, individuals may grapple with daytime lethargy. Hypersomnia, characterized by persistent daytime sleepiness and struggles to remain awake, differs from narcolepsy in the absence of sudden and involuntary sleep episodes.
Narcolepsy, a rarer and more severe condition, epitomizes excessive daytime sleepiness, often compounded by unpredictable bouts of slumber at inconvenient times. Individuals afflicted with narcolepsy may succumb to sleep without warning and find it challenging to stay alert during the day. Unlike hypersomnia, narcolepsy is typified by disrupted nighttime sleep, further compromising overall sleep quality. Given its chronic nature, managing narcolepsy necessitates ongoing treatment and care. To effectively address excessive daytime sleepiness, understanding its multifaceted causes is imperative. By identifying and treating the underlying conditions such as sleep apnea, RLS, depression, hypersomnia, or narcolepsy, tailored interventions can be devised to enhance sleep quality and mitigate daytime drowsiness.
""Excessive Daytime Sleepiness- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Excessive Daytime Sleepiness pipeline landscape is provided which includes the disease overview and Excessive Daytime Sleepiness treatment guidelines. The assessment part of the report embraces, in depth Excessive Daytime Sleepiness commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Excessive Daytime Sleepiness collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Excessive Daytime Sleepiness R&D. The therapies under development are focused on novel approaches to treat/improve Excessive Daytime Sleepiness.
This segment of the Excessive Daytime Sleepiness report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Excessive Daytime Sleepiness Emerging Drugs
AXS-12: Axsome Therapeutics
AXS-12 (reboxetine) is a highly selective and potent norepinephrine reuptake inhibitor being developed for the treatment of narcolepsy. It is thought to modulate noradrenergic activity to promote wakefulness, maintain muscle tone and enhance cognition. Reboxetine has an extensive safety record in Europe and in over 40 countries where it’s approved for the treatment of depression. In narcolepsy, AXS-12 is supported by positive pre-clinical and Phase II clinical results. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Excessive Daytime Sleepiness.
ALKS 2680: Alkermes
ALKS 2680 is a novel, investigational, oral, selective orexin 2 receptor (OX2R) agonist in development for the treatment of narcolepsy. Orexin neuropeptides are important regulators of the sleep/wake cycle through OX2R activation, and loss of orexinergic neurons in the brain is associated with excessive daytime sleepiness and cataplexy in narcolepsy.1 ALKS 2680 was designed to address the underlying pathology of narcolepsy with the goal of improving duration of wakefulness and providing cataplexy control. Once-daily oral administration of ALKS 2680 is currently being evaluated in a phase II study for the treatment of idiopathic hypersomnia.
Further product details are provided in the report……..
Excessive Daytime Sleepiness: Therapeutic Assessment
This segment of the report provides insights about the different Excessive Daytime Sleepiness drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Excessive Daytime Sleepiness
- There are approx. 10+ key companies which are developing the therapies for Excessive Daytime Sleepiness. The companies which have their Excessive Daytime Sleepiness drug candidates in the most advanced stage, i.e. Phase III include, Axsome Therapeutics.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Excessive Daytime Sleepiness: Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Excessive Daytime Sleepiness therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Excessive Daytime Sleepiness drugs.
Excessive Daytime Sleepiness Report Insights
- Excessive Daytime Sleepiness Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Excessive Daytime Sleepiness drugs?
- How many Excessive Daytime Sleepiness drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Excessive Daytime Sleepiness?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Excessive Daytime Sleepiness therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Excessive Daytime Sleepiness and their status?
- What are the key designations that have been granted to the emerging drugs?
- Suven Life Sciences Limited
- NLS Pharmaceutics
- Axsome Therapeutics
- Zevra Therapeutics
- Jazz Pharmaceuticals
- SUVN-G3031
- Mazindol extended release
- AXS-12
- KP1077
- JZP441
Table of Contents
60 Pages
- Introduction
- Executive Summary
- Excessive Daytime Sleepiness: Overview
- Introduction
- Causes
- Pathophysiology
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Excessive Daytime Sleepiness– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- AXS-12: Axsome Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- ALKS 2680: Alkermes
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Excessive Daytime Sleepiness Key Companies
- Excessive Daytime Sleepiness Key Products
- Excessive Daytime Sleepiness- Unmet Needs
- Excessive Daytime Sleepiness- Market Drivers and Barriers
- Excessive Daytime Sleepiness- Future Perspectives and Conclusion
- Excessive Daytime Sleepiness Analyst Views
- Excessive Daytime Sleepiness Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
